Latham & Watkins Advises Financing Sources in Up to US$1.2 Billion Growth Financing, One of the Largest Healthcare Financings of 2026, for Caris Life Sciences

Caris Life Sciences, Inc. has announced that it has entered into a new senior secured credit agreement providing an initial term loan of US$400 million, a committed delayed draw term facility of up to US$300 million, and an uncommitted incremental facility of up to US$500 million. The initial term loan funded at closing and matures in April 2031, and the delayed draw facility is available through August 2027 for permitted acquisitions. The facilities are guaranteed by certain subsidiaries and secured by substantially all tangible and intangible personal property. Proceeds from the initial term loan were used to fully repay and terminate the company’s January 18, 2023 credit agreement, including related guarantees and liens.

Latham & Watkins LLP represented Blue Owl and Blackstone in the transaction with a corporate team led by partners Haim Zaltzman, Stelios Saffos, Peter Sluka, and Michael Waldman, and counsel Benjamin Gelfand, with associates Axel Magnusson and William Lane. Advice was also provided on healthcare regulatory matters by partner Betty Pang; on FDA matters by partner Nathan Beaton; on intellectual property and royalty matters by partner Todd Trattner; on HIPAA and data privacy matters by partner Heather Deixler, with associate Chad Leiper; on tax matters by partner Bora Bozkurt, with assistance from George Yu; and on derivatives matters by partner Reza Mojtabaee‑Zamani.